

Expect Changes to Prevnar 13 Recommendations for Healthy Seniors

You'll start to see **LESS focus on giving Prevnar 13 to healthy seniors**...due to changes in CDC guidelines expected this fall.

We're used to giving immunocompetent adults 65 and older *Prevnar 13* followed by *Pneumovax 23* one year later...based on 2014 recommendations.

The idea was to further decrease pneumococcal infection rates.

But it turns out that seniors are mainly protected from strains in *Prevnar 13* by "herd immunity"...thanks to successful vaccination of kids.

Expect updated CDC recommendations to advise "shared clinical decision-making" with seniors when considering *Prevnar 13*. Be aware, your standing order may not change until the final guidelines are published.

Reassure that there aren't safety concerns with *Prevnar 13*. But there doesn't seem to be much benefit. Help healthy seniors decide about *Prevnar 13* with our patient handout, *Which Pneumonia Vaccine Do I Need?*

Explain that *Prevnar 13* prevents just 1 case of outpatient pneumonia for every 2,600 healthy seniors immunized per year.

And giving *Prevnar 13* to healthy seniors only prevents 1 case of invasive pneumococcal disease for every 26,300 immunized per year.

Plus *Prevnar 13* costs about \$190/dose.

Focus on giving *Pneumovax 23* to seniors 65 and older. It protects against 11 serotypes not covered by herd immunity from *Prevnar 13*.

For now, when healthy seniors choose to get both vaccines, continue to give *Prevnar 13* first...then *Pneumovax 23* one year later. Medicare Part B still covers both if they're spaced at least one year apart.

Advise that immunocompromised adults (chronic renal failure, etc) of any age get both vaccines. Give *Prevnar 13*, then *Pneumovax 23* at least 8 weeks later...to limit unprotected time in these more vulnerable patients.

And continue to recommend *Pneumovax 23* for adults UNDER 65 who smoke or have chronic conditions...and *Prevnar 13* as a routine vaccine in kids.

Use our *Pneumococcal Vaccination in Adults: Who Gets What and When?* chart to find out what to recommend for your patient.

Key References:

- www.cdc.gov/vaccines/acip/meetings/slides-2019-06.html (08-16-19)
- MMWR Morb Mortal Wkly Rep 2015;64(34):944-7
- MMWR Morb Mortal Wkly Rep 2014;63(37):822-5
- Medication pricing by Elsevier, accessed Aug 2019

Pharmacist's Letter. September 2019, No. 350901

Cite this document as follows: Article, Expect Changes to Prevnar 13 Recommendations for Healthy Seniors, Pharmacist's Letter, September 2019

The content of this article is provided for educational and informational purposes only, and is not a substitute for the advice, opinion or diagnosis of a trained medical professional. If your organization is interested in an enterprise subscription, email sales@trchealthcare.com.

© 2019 Therapeutic Research Center (TRC). TRC and Pharmacist's Letter and the associated logo(s) are trademarks of Therapeutic Research Center. All Rights Reserved. | 3120 W. March Lane, Stockton, CA, 95219 | (209) 472-2240